Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152 · MAPKeeper 301 Phase 3Recruiting
- Lead sponsor
- Immuneering Corporation (Industry)
- Enrollment
- 510 (estimated)
- Start date
- 5 Jun 2026
- Primary completion
- Jun 2028 (estimated)
- Study completion
- 1 Feb 2029
- Last update posted
- 30 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Atebimetinib Drug
- GnP Drug
- mGnP Drug
Conditions and primary outcome
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma
Primary outcome
Overall Survival (Up to approximately 2 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07562152.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07562152 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.